Moderna Inc
Stocks making the greatest moves midday: Boeing, Norfolk Southern, Nvidia & more
Check out out the corporations earning headlines in midday investing. BlackBerry — BlackBerry shares popped more than 9% immediately after the business announced a partnership with Sophisticated Micro Equipment on robotics programs. Moderna — The vaccine maker received 6%. Reuters claimed that Moderna’s most cancers drug it is performing on with Merck confirmed promising results […]
Read More
Shares producing the biggest moves midday: GameStop, Merck, Carnival, Cintas and far more
Verify out the firms creating headlines in midday trading. GameStop — GameStop shed 15% following the video recreation retailer claimed decreased fourth-quarter income from a yr ago. The corporation also stated it axed an unspecified amount of roles to trim expenditures. Merck — Merck jumped 5% immediately after the U.S. Foodstuff and Drug Administration on […]
Read More
Stocks earning the greatest moves premarket: Robinhood, GameStop, Merck and additional
Look at out the firms building headlines in premarket investing. Robinhood — Shares of the brokerage business jumped additional than 6% immediately after unveiling its Robinhood Gold Card, a credit rating card wherever funds again can be deposited into a brokerage account. Concentrix — Shares slipped approximately 4% on the back of disappointing fiscal second-quarter […]
Read More
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
Nikos Pekiaridis | Lightrocket | Getty Images Moderna has more to offer beyond its Covid vaccine. The biotech company made that clear on Wednesday, announcing positive clinical trial data on three experimental vaccines for other diseases. The company is moving those shots to final stage studies, it said. The update brings Moderna a step closer […]
Read More
Moderna says new Covid vaccine showed stronger immune response than current shot in study
A nurse fills a syringe with Moderna Covid-19 vaccine. Fred Tanneau | Afp | Getty Images Moderna on Tuesday said a new version of its Covid vaccine triggered a stronger immune response against the virus than its current shot in a late-stage trial. The results come as Moderna competes with rival Pfizer for more share […]
Read More
Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot’s efficacy declined slightly compared with the levels of protection after one RSV season, but the […]
Read More
Moderna posts surprise quarterly profit even as Covid vaccines sales plummet
Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge […]
Read More
S&P 500 futures increase in right away buying and selling, Nvidia shares leap: Dwell updates
Traders on the flooring of the New York Stock Exchange on Aug. 4, 2022. Source: NYSE S&P 500 futures rose in right away trading Wednesday, boosted by a soar in Nvidia shares as the chip giant posted report profits and issued upbeat advice. S&P 500 futures climbed .7% and Nasdaq 100 futures attained a lot […]
Read More
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion, in […]
Read More
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a […]
Read More